Experimental drug combo for head and neck cancer shows early promise
NCT ID NCT06110195
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested an experimental drug called xevinapant combined with standard chemotherapy and radiation in people with head and neck cancer who cannot take the usual drug cisplatin. The goal was to find the safest dose of xevinapant. The study was terminated early, so results are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
xevinapant (an experimental drug taken orally)
What this could lead to
If it works, this could point toward a new treatment option for head and neck cancer patients who cannot receive standard cisplatin chemotherapy.
What could go wrong
This is a very early (phase 1) trial that was terminated, so results are limited. The combination may cause significant side effects, and the drug may not improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Chicago Medicine Comprehensive Cancer Center
Chicago, Illinois, 60637, United States